Chi Ma

Disease Areas： Lung Cancer, Gastric cancer, Colorectal cancer, Esophageal cancer，Lung Cancer Innovative Products：not limited to Camrelizumab for injection (PD-1 inhibitor), Apatinib mesylate Tablets (targeted anti-angiogenesis), Pyrotinib Maleate Tablets （HER2 inhibitor），Paclitaxel for Injection (Albumin Bound) ， Fluzoparib Capsules(PARP inhibitor) and Bevacizumab injection. Role：National medical strategy development through leading MA team; more than 20 IIT management; innovative drug launch readiness; TOP KOL engagement;Cross function cooperation

DA: Gastrointestinal/ Gynecologic/Central nervous system Oncology （1）Hepatocellular carcinoma Product：PD-L1 inhibitor TECENTRIQ, Anti-angiogenesis AVASTIN Launch Readiness acceration for global First HCC immunotherapy combination Innovative treatment （2）Gastrointestinal Oncology (Gastric and colorectal cancer), Gynecologic Oncology (Cervical, Ovarian cancer，Endometrial cancer), Central nervous system tumor-Glioblastoma(GBM) Products: AVASTIN®, bevacizumab; HERCEPTIN®, trastuzumab;XELODA®, capecitabine

Therapeutic Areas / Products: Nephrology ( CALCIJEX®, Calcitriol Injection; Zemplar®, Paricalcitol Injection) MSL Covering North and Northeast China

Clinical Study management，mainly focus on global Phase III oncology(HCC,CRC, BC) and CVD areas

Peking University First Hospital Resistance selection by Linezolid in Staphylococcus aureus in an in vitro dynamic model with simulated normal human pharmacokinetics.( Pfizer, Protocol designer ) In-vitro post-antibiotic effect (PAE)of new fluoroquinolones Antofloxacin . (Leader)  Pharmacokinetics/pharmacodynamics (PK/PD)of Itraconazole and hydroxyitraconazole (Johnson & Johnson ) Single dose tolerance test of Chinfloxacin tablet in healthy human. (Assistant) Pharmacokinetic study of Ustekinumab in Chinese Male Subjects in a single dose subcutaneous injection of 45or90mg. Bioequivalence study of oral domestic and imported Mizolastine in healthy volunteers (Assistant)